Compare Nvidia Corp (NVDA) vs Novartis AG (NVS) Price & Performance

Nvidia CorpTrade

Novartis AGTrade

Price performance (Past 24H)

Key statistics

Nvidia Corp vs Novartis AG — how do they compare? Nvidia Corp trades at $206.69 (market cap $4.92T), while Novartis AG trades at $153.88 (market cap $290.25B). The key difference: Nvidia Corp is far larger — about 17× Novartis AG's market cap, and Novartis AG pays the higher dividend (3.17%). Which is the better fit depends on your goals.

	NVDA	NVS
Market Cap	$4.92T	$290.25B
Sector	Technology	Health
52-Week High	$235.75	$168.62
52-Week Low	$165.17	$113.50
Enterprise Value	$4.86T	$330.27B
Dividend Yield	0.49%	3.17%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Nvidia Corp

Nvidia (NVDA) trades at $207.14, up 2.14% today, with a neutral technical signal and strong fundamental performance. Recent earnings consistently beat estimates, with Q1 2026 EPS of $1.87 exceeding the $1.76 forecast. Revenue surged to $130.50B in 2025, driving a net income margin of 62.97%. The stock faces resistance near $210, while support holds at $201.

Outlook remains positive due to AI-driven growth and robust profitability, but risks include peak AI spending concerns and competitive pressures. Analysts project a $325.86 price target, with 75% recommending Buy. Investors should weigh high valuation multiples against sustained earnings momentum.

Novartis AG

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NVDA

Amplify CWP Growth & Income ETF offers 10.69% yield with tech focus, rated a BUY for income portfolios.Seeking Alpha · 5 hours agoBullish Roundhill Magnificent Seven ETF offers equal exposure to top 7 mega-cap tech stocks but with higher risk and cost.24/7 Wall Street · 6 hours agoNeutral Nvidia faces pressure from cheaper Chinese chips but bets on AI and emerging tech for growthSeeking Alpha · 7 hours agoNeutral View details →

NVS

Novartis Q2 earnings expected at $2.17 EPS, $14.07B revenue amid patent loss impact and key drug trials ahead.Gordon Thompson · 1 day agoNeutral New report details 1,230+ bioinformatics deals, revealing market trends and deal structures through 2026Researchandmarkets.Com · 4 days agoNeutral FDA approves Fabhalta as first drug to significantly slow kidney decline in IgAN patientsNovartis · 4 days agoBullish View details →

About Nvidia Corp

NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.